Truist lowered the firm’s price target on Praxis Precision (PRAX) to $85 from $175 and keeps a Buy rating on the shares. The firm is removing ulixacaltamide in essential tremor, ET, sales from its model after the company disclosed last week that Independent Data Monitoring Committee recommended that its study be stopped for futility due to the results being unlikely to meet the primary efficacy endpoint, the analyst tells investors in a research note.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target lowered to $120 from $170 at Guggenheim
- Praxis Precision price target lowered to $85 from $150 at Needham
- Praxis Precision price target lowered to $73 from $117 at Baird
- Praxis Precision Medicines: A Compelling Buy Amidst Promising Pipeline Developments
- Praxis Precision price target lowered to $105 from $120 at H.C. Wainwright